VC-backed Audentes debuts IPO
San Francisco-based Audentes Therapeutics, a developer of gene therapy products for patients with serious, life-threatening rare diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 20, 2016 on the NASDAQ under the ticker symbol "BOLD." BofA Merrill Lynch, Cowen and Company and Piper Jaffray are serving as the lead underwriters. Audentes' backers included Deerfield Management, Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures.
20 July 2016•2 mins read
